## Note
nid: 1495632166665
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#FirstAid::01_Biochemistry::05_Nutrition::04_Vitamin_A, #AK_Step1_v11::#FirstAid::01_Biochemistry::05_Nutrition::04_Vitamin_A::Function, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::04_Pathology::28_Leukemia::Acute_Leukemia::Acute_Myelogenous_Leukemia::Acute_Promyelocytic_Leukemia, #AK_Step1_v11::#OME_banner::Basic_Science::02_Metabolism, #AK_Step1_v11::#Physeo::05_Biochem::05_Metabolism::38_Vitamin_A_-_Nutrition, #AK_Step1_v11::#Pixorize::01_Immunology::07_Leukemias_&_Lymphomas::02_APL, #AK_Step1_v11::#Pixorize::02_Biochem::01_Vitamins::13_Vitamin_A_(Retinol)_Biochem, #AK_Step1_v11::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::02_Acute_Myeloid_Leukemia_(AML)_&_Chronic_Myeloid_Leukemia_(CML), #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::Retinoids_BCG, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::1-HighYield
markdown: false

### Text
<div>
  In the treatment of <u>Acute Promyelocytic Leukemia,</u>
  <b>all</b><b>-trans retinoic acid (ATRA</b><b style=
  "font-weight: normal;">)</b> prevents differentiation from being
  halted at the {{c1::<b style=
  "font-weight: normal;">promyelocyte</b>}} <b style=
  "font-weight: normal;">stage</b>
</div>

### Extra
<div>
  <div>
    This allows normal mature granulocytes to populate the bone
    marrow
  </div>
</div>
<div><img src=
"Figure-2-Mechanism-of-action-of-ATRA-PML-RARa-fusion-protein-forms-a-complex-with.png"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
<div><img src="APL%20all-trans-retinoic%20acid_1566160514431.jpg"
class="resizer"><img src=
"Zoverall%20picture%20(80)_1566160514431.JPG" class=
"resizer"></div>

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/metabolism?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_4.png"></a>
</div>

### Additional Resources


### One by one

